InnoPharma LABORATORIO	**TECHNICAL INFORMATION** **VETERINARY PRODUCTS**
	CLINDAMYCIN **100 mg / mL** **INJECTABLE SOLUTION**

CLINDAFUR

Registration Number Q-0666-038

FORMULA:

Each mL contains:
Clindamycin phosphate equivalent to
Clindamycin.....100.0 mg
Vehicle q.s. ..... 1 mL

INDICATIONS:

CLINDAFUR, is a broad-spectrum antibiotic indicated for the treatment of pulmonary infections, osteoarthritis, prostate soft tissue skin and in cases of toxoplasmosis.

Characteristics:

Clindamycin is a semisynthetic antibiotic, originated fromStreptomyces lincolnensis var. lincolnensis, It is a chlorinated derivative of Lincomycin., which differs structurally from this compound by the substitution of a chlorine atom by a hydroxyl group and the inversion of the carbon at position 7, which is an amino acid attached to an amino sugar. It is generally bacteriostatic, but can be bactericidal depending on its concentration. It is also widely distributed in most body tissues.



Clindamycin is soluble in water, has a pKa of 7.45. The MIC of Clindamycin for most susceptible anaerobic bacteria is 0.1-4 µg/mL.

There are studies carried out by different authors that indicate the existence of subclinical infections of neosporosis in the canine population, the treatment of choice that is very effective is the combination of clindamycin and trimethoprim-sulfonamides.

Clndafur in dogs and cats is effective for the treatment of dermatological, genitourinary, gastrointestinal, respiratory, bone and soft tissue infections caused by microorganisms susceptible to clindamycin such as Gram positive aerobic bacteria Staphylococcus, Streptococcus pneumoniae and a primary effect on Gram positive and Gram negative anaerobes such as: *Actinomyces sp, Bacteroides spp, Clostridium spp, Fusobacterium, Staphylococcus aureus and Streptococcus pyogen, as well as Chlamydia sp and Mycoplasma sp. Its use in conjunction with other drugs has been used to treat protozoan infections such as Toxoplasma gondii and Neospora caninum.*

InnoPharma LABORATORIO	**TECHNICAL INFORMATION** **VETERINARY PRODUCTS**
	CLINDAMYCIN **100 mg / mL** **INJECTABLE SOLUTION**

Clindamycin is the most effective in the treatment of infections caused by anaerobic anaerobes.

PHARMACOLOGY

Clindamycin acts by inhibiting protein synthesis after reversibly binding to the 50S subunit of the bacterial ribosome. This binding inhibits bacterial protein synthesis by interfering with the binding of complexes and with the amino acid translocation reaction, preventing the action of peptidyltransferase, its binding to proteins is very high. After being metabolized some metabolites continue to have antibacterial activity, since it accumulates in macrophages and even in abscesses.
It is generally considered bacteriostatic, but can be bactericidal when used in high concentrations or against highly sensitive organisms. It actively accumulates in white blood cells reaching bactericidal concentrations in several sites.

At the concentration reached in the tissues, with the usual doses, clindamycin has bacteriostatic activity and postantibiotic effect. Apart from its antimicrobial activity, clindamycin can decrease the formation of bacterial glycocalyx and the production of different toxins (alpha toxin, toxic shock syndrome toxin, LPV) and can increase the phagocytic activity of polymorphonuclear leukocytes.

Most gram-positive aerobic cocci are susceptible to clindamycin, including Staphylococcus and Streptococcus, and other Corynebacterium, Nocardia asteroides, Erysipelothrix, Toxoplasma, Chlamydia sp and Mycoplasma sp. Anaerobic bacteria that are generally susceptible to this drug are: Clostridium perfringens, C. tetani, Bacteroides Fusobacterium, Actinomyces.

PHARMACOKINETICS

Clindamycin has a high absorption in the gastrointestinal tract producing very high serum concentrations, due to the substitution of the hydroxyl radical by chlorine, which represents a high bioavailability. The elimination half-life is 3 hours 12 minutes.
It is widely and rapidly distributed in most fluids and tissues, except in cerebrospinal fluid, reaching high concentrations in bone, bile and urine, it even crosses the placental barrier being useful in intrauterine infections by anaerobic bacteria.
It is metabolized by the liver and some metabolites may still have antibacterial activity, 90% of the inactive clindamycin is eliminated in urine and the rest in bile and feces. It is also excreted in breast milk; the half-life of the drug may increase in patients with markedly decreased renal function, and/or in those with hepatic insufficiency.

CONTRAINDICATIONS:

Clindamycin should be used with caution in cats with pulmonary toxoplasmosis. Since, some investigations have indicated the death of several cats with this type of toxoplasmosis, after the administration of Clindamycin parenterally.
Use during pregnancy has not shown teratogenic effects; however, during lactation, puppies may present

diarrhea.

GENERAL PRECAUTIONS:
Not recommended for use in animals sensitive to the formula, with hepatic and/or renal disease.

WARNINGS:
Some gastrointestinal adverse effects may occur with oral and intramuscular use consisting of nausea, vomiting, diarrhea, abdominal pain and tenesmus, reversible increase in liver transaminases, thrombocytopenia and granulocytopenia.

DOSAGE AND ROUTE OF ADMINISTRATION:
Use in: Domestic canines and felines.
Route of administration: Intramuscular 5 to 10 mg/ kg of body weight (1 ml or every 2ks in high dose 1 ml or every 1 kg every 12 hrs during 5 to 7 days, the duration of the treatment was according to each clinical case).

Size	Kg of weight	mL
Miniature	1 to 4	1
Small	5 to 10	1.25 – 2.5
Medium	11 to 20	2.5 – 5
Large	21 to 30	5 - 7.5
	30 to 40	7.5 – 10
	40 to 50	10 -12.5
Gigant	51 to 60	12.5 – 15
	60 to 70	15 – 17.5

Domestic felines:

Size	Kg of weight	mL
Pequeña	1 to 3	0.5 – 1
Mediana	3 to 5	1 – 1.5
Grande	5 to 6	1.5 - 2

Every 12 hours for 5 to 7 days according to the clinical case and criteria of the Veterinary Doctor.

PRESENTATION:

InnoPharma® LABORATORIO	**TECHNICAL INFORMATION** **VETERINARY PRODUCTS**
	CLINDAMYCIN **100 mg / mL** **INJECTABLE SOLUTION**

Box with vial with powder for oral solution and dosing syringe.
Bottle with 30 mL when reconstituted.

STORAGE RECOMMENDATIONS:
Store in a cool, dry place at no more than 30° C (86° F).

PROTECTION PRECAUTIONS:
Consult a Veterinarian. Keep out of reach of children and domestic animals.
PRODUCT FOR EXCLUSIVE USE IN VETERINARY MEDICINE.
GLP23

MADE IN MEXICO BY:
INNOPHARMA, S. DE R. L. DE C.V.
Av. San Pablo, No 79-C
Col. Santa Bárbara,
Alc. Azcapotzalco, CP 02230,
Ciudad de México.
Tel: (55) 5382 2289
ventas@innopharma.com.mx
www.innopharma.com.mx